Wire · opportunities
Lung cancer drug doubles survival in trial: What to know
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
BioNTech and OncoC4's immunotherapy drug Gotistobart nearly doubled median overall survival to 18.5 months versus 10 months with standard chemotherapy in previously treated squamous non-small cell lung cancer patients, based on new trial data presented at the 2026 World Conference on Lung Cancer.
This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery, and 3 sources have reported it between 14 Sep 2026 and 18 Sep 2026.
◆ ◆ The Wire takeaway
You must engage with immunotherapy innovations now as gotistobart resets survival expectations in lung cancer. This shifts opportunity to develop new cancer treatments that can outperform standard chemotherapy.
◆ Coverage
3 sources · first reported 14 Sep 2026 · latest 18 Sep 2026
◆ Related on Wire
◆ Topics